Sildenafil: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Sildenafil, so there is currently no new predicted indication. The drug’s own recorded uses are listed below. They are not model candidates.
Quick overview
Item
Content
New predicted indications
None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug
6
Evidence level
Not applicable
Australia Market Status
Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items
1 (valid: 1)
Known uses recorded for this drug
Approved (supported by a licence or label)
Indication
Source
erectile dysfunction
licence in another country
hypertension
licence in another country
pulmonary hypertension
licence in another country
Related to an approved indication (same disease category)
Indication
Approved category
none
none
Relations recorded in the knowledge graph (no approval found)
Indication
premature ejaculation
psychologic dyspareunia
pulmonary arterial hypertension
Australia Market Information
Licence
Product
Dosage form
Status
12138W
Sildenafil Sandoz PHT 20
Tablet 20 mg (as citrate)
Valid
Safety Considerations
The following comes from knowledge-graph contraindication links, not from label text. Please confirm against the TGA-approved Product Information (PI).
Disease-level contraindication signals (knowledge graph): liver failure; aortic stenosis and other aortic valve disease; hypotensive disorders; acute coronary syndrome; myocardial infarction; stroke and cerebrovascular disorders; sickle cell anaemia and other haemoglobinopathies; plasma cell myeloma; leukaemia; priapism; Peyronie disease; hypertrophic cardiomyopathy; anterior ischaemic optic neuropathy; pulmonary veno-occlusive disease; hearing loss disorders; oesophageal dyskinesia.
Drug interactions: 100 interactions were identified in total. Of the 20 shown, the one rated Major is clarithromycin. Most others are rated Moderate, including aprepitant, morphine, dexamethasone, cimetidine, miconazole, clotrimazole, papaverine, opium, and the SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin). Calcitriol, acarbose and sucralfate are rated Unknown.
Hair-related caution: Hypertrichosis is a known adverse effect of KATP channel openers such as minoxidil, so any hair effect of sildenafil would need direct testing.
Please refer to the TGA-approved PI for the official warnings and contraindications, as label-level data were not available.
Disclaimer
This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.